PriceTargets.com logo

Clover Health Investments - CLOV Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.93
  • Forecasted Upside: 47.56%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.66 As of 12/4/2025 05:00 PM ET
▲ +0.04 (1.53%)

This chart shows the closing price for CLOV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Clover Health Investments Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLOV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLOV

Analyst Price Target is $3.93
▲ +47.56% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Clover Health Investments in the last 3 months. The average price target is $3.93, with a high forecast of $6.00 and a low forecast of $3.00. The average price target represents a 47.56% upside from the last price of $2.66.

This chart shows the closing price for CLOV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 6 polled investment analysts is to hold stock in Clover Health Investments. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/25/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/24/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
11/19/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/6/2025Canaccord Genuity GroupLower TargetBuy ➝ Buy$4.10 ➝ $3.70
10/24/2025Zacks ResearchUpgradeHold ➝ Strong-Buy
10/21/2025Leerink PartnersSet TargetMarket Perform ➝ Market Perform$3.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/7/2025Canaccord Genuity GroupLower TargetBuy ➝ Buy$4.50 ➝ $4.10
8/6/2025UBS GroupLower TargetNeutral ➝ Neutral$4.50 ➝ $3.00
3/3/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$4.20 ➝ $4.50
12/17/2024Craig HallumInitiated CoverageBuy$6.00
10/7/2024UBS GroupInitiated CoverageNeutral$4.00
8/11/2023CitigroupBoost TargetNeutral ➝ Neutral$1.00 ➝ $1.50
5/12/2023CitigroupLower Target$1.30 ➝ $1.00
3/6/2023Canaccord Genuity GroupLower TargetBuy$4.00 ➝ $3.00
3/6/2023Credit Suisse GroupLower TargetUnderperform$2.50 ➝ $1.25
11/16/2022CowenLower Target$1.75
11/16/2022CitigroupLower TargetNeutral$3.50 ➝ $1.80
11/8/2022Canaccord Genuity GroupLower Target$7.00 ➝ $4.00
11/8/2022Leerink PartnersLower TargetMarket Perform$3.00 ➝ $1.50
8/15/2022CitigroupBoost Target$3.50
8/9/2022Credit Suisse GroupLower TargetUnderperform$3.50 ➝ $3.00
8/9/2022CitigroupBoost TargetNeutral$3.00 ➝ $3.50
2/25/2022Leerink PartnersLower TargetMarket Perform$3.00 ➝ $2.50
2/24/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$6.00 ➝ $7.00
2/2/2022CowenUpgradeUnderperform ➝ Market Perform$7.00 ➝ $3.00
2/2/2022Canaccord Genuity GroupInitiated CoverageBuy$6.00
1/19/2022Leerink PartnersInitiated CoverageMarket Perform$3.00
1/7/2022Credit Suisse GroupDowngradeNeutral ➝ Underperform$9.00 ➝ $3.50
11/15/2021Credit Suisse GroupBoost TargetNeutral$8.00 ➝ $9.00
9/9/2021CowenInitiated CoverageUnderperform$7.00
9/2/2021CitigroupInitiated CoverageNeutral$10.00
7/12/2021JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$9.00
6/10/2021Bank of AmericaDowngradeNeutral ➝ Underperform$10.00
5/24/2021Bank of AmericaReiterated RatingBuy ➝ Neutral$15.00 ➝ $9.00
5/19/2021Credit Suisse GroupLower TargetNeutral$10.00 ➝ $9.00
5/18/2021CitigroupLower TargetBuy$13.00 ➝ $10.00
5/17/2021Bank of AmericaDowngradeBuy ➝ Neutral$15.00 ➝ $9.00
3/9/2021Credit Suisse GroupInitiated CoverageNeutral$10.00
3/3/2021CitigroupLower Target$19.00 ➝ $13.00
2/2/2021CitigroupInitiated CoverageBuy$19.00
2/1/2021JPMorgan Chase & Co.Initiated CoverageNeutral$15.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.75 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 15 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 15 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 14 very positive mentions
  • 27 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 19 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
9/5/2025
  • 5 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 9 very positive mentions
  • 22 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 11 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 11 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Clover Health Investments logo
Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat. Clover Health Investments, Corp. is based in Franklin, Tennessee.
Read More

Today's Range

Now: $2.66
Low: $2.58
High: $2.72

50 Day Range

MA: $2.81
Low: $2.16
High: $3.82

52 Week Range

Now: $2.66
Low: $2.12
High: $4.87

Volume

4,735,455 shs

Average Volume

5,885,877 shs

Market Capitalization

$1.37 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.24

Frequently Asked Questions

What sell-side analysts currently cover shares of Clover Health Investments?

The following sell-side analysts have issued research reports on Clover Health Investments in the last twelve months: Canaccord Genuity Group Inc., Craig Hallum, Leerink Partners, UBS Group AG, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for CLOV.

What is the current price target for Clover Health Investments?

0 Wall Street analysts have set twelve-month price targets for Clover Health Investments in the last year. Their average twelve-month price target is $3.93, suggesting a possible upside of 47.6%. Craig Hallum has the highest price target set, predicting CLOV will reach $6.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $3.00 for Clover Health Investments in the next year.
View the latest price targets for CLOV.

What is the current consensus analyst rating for Clover Health Investments?

Clover Health Investments currently has 1 sell rating, 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CLOV, but not buy more shares or sell existing shares.
View the latest ratings for CLOV.

What other companies compete with Clover Health Investments?

Other companies that are similar to Clover Health Investments include Hagerty, Oscar Health, F&G Annuities & Life, Alignment Healthcare and Brighthouse Financial. Learn More about companies similar to Clover Health Investments.

How do I contact Clover Health Investments' investor relations team?

Clover Health Investments' physical mailing address is 317 University Ave Suite 200, Palo Alto CA, 94301. The company's listed phone number is 201-432-2133 and its investor relations email address is [email protected]. The official website for Clover Health Investments is www.cloverhealth.com. Learn More about contacing Clover Health Investments investor relations.